Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20953440 | 0.79 | PTGS2 (0.38) | PTGS2SLC1A3 | |
| SCHEMBL23651542 | 0.76 | PTGS2 (0.34) | PTGS2SLC1A3 | |
| SCHEMBL5995366 | 0.72 | SLC1A3 (0.41) | PTGS2SLC1A3 | |
| SCHEMBL2646281 | 0.67 | — | — | |
| SCHEMBL25043902 | 0.66 | HSD11B1 (0.38) | — | |
| SCHEMBL25414716 | 0.64 | GGPS1 (0.35) | PTGS2 | |
| SCHEMBL27157224 | 0.62 | — | — | |
| SCHEMBL27157231 | 0.62 | — | — | |
| SCHEMBL24828647 | 0.62 | — | — | |
| SCHEMBL25412237 | 0.62 | MAPK1 (0.36) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA AS (DK) | 2025-06-19 | — | — | US | disclosed |
| EP-4486737-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | PTGS2 308/4885SLC1A3 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.